Cited by 127Histone Deacetylase Inhibitors ResearchGenomics and Chromatin DynamicsEpigenetics and DNA Methylation

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells

Open access

Caslini, Corrado, Hong, Sunhwa, Ban, Yuguang J., Chen, Xi S., Ince, Tan A.·2019·Oncogene

Open this paper in CoChat — free account Open PDF

Abstract

Chromatin regulation through histone modifications plays an essential role in coordinated expression of multiple genes. Alterations in chromatin induced by histone modifiers and readers regulate critical transcriptional programs involved in both normal development and tumor differentiation. Recently, we identified that histone deacetylases HDAC1 and HDAC7 are necessary to maintain cancer stem cells (CSCs) in both breast and ovarian tumors. Here, we sought to investigate the CSC-specific function of HDAC1 and HDAC7 mechanistically by using a stem-like breast cancer (BrCa) cell model BPLER and matched nonstem tumor cell (nsTC)-like HMLER, along with conventional BrCa cell lines with different CSC enrichment levels. We found that HDAC1 and HDAC3 inhibition or knockdown results in HDAC7 downregulation, which is associated with a decrease in histone 3 lysine 27 acetylation (H3K27ac) at transcription start sites (TSS) and super-enhancers (SEs) prominently in stem-like BrCa cells. Importantly, these changes in chromatin landscape also correlate with the repression of many SE-associated oncogenes, including c-MYC, CD44, CDKN1B, SLUG, VDR, SMAD3, VEGFA, and XBP1. In stem-like BrCa cells, HDAC7 binds near TSS and to SEs of these oncogenes where it appears to contribute to both H3K27ac and transcriptional regulation. These results suggest that HDAC7 inactivation, directly or through inhibition of HDAC1 and HDAC3, can result in the inhibition of the CSC phenotype by downregulating multiple SE-associated oncogenes. The CSC selective nature of this mechanism and the prospect of inhibiting multiple oncogenes simultaneously makes development of HDAC7 specific inhibitors a compelling objective.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41388-019-0897-0

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update
Afgan, E., Baker, D., Batut, B., van den Beek, M., Bouvier, D., Čech, M., Chilton, J., Clements, D., Coraor, N., Grüning, B. A., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky379 · Cited by 3,662
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,234
Erasers of Histone Acetylation: The Histone Deacetylase EnzymesPreprint
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 2,105
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy
Brainson, C. F., & Kuperwasser, C. (2008) · Breast Cancer Research · doi:10.1186/bcr1982 · Cited by 1,049
Enhancer decommissioning by LSD1 during embryonic stem cell differentiation
Whyte, W. A., Bilodeau, S., Orlando, D. A., Hoke, H. A., Frampton, G. M., Foster, C. T., Cowley, S. M., & Young, R. A. (2012) · Nature · doi:10.1038/nature10805 · Cited by 602
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer
Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575
Untitled work
(2003) · PubMed · Cited by 519

Show all 45 references

Sorted by citations

Modulation of cellular processes by histone and non-histone protein acetylation
Shvedunova, M., & Akhtar, A. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00441-y · Cited by 1,007
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 365
Liquid–liquid phase separation in tumor biology
Tong, X., Tang, R., Xu, J., Wang, W., Zhao, Y., Yu, X., & Shi, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01076-x · Cited by 265
Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress
Неганова, М. Е., Klochkov, S. G., Aleksandrova, Y. R., & Aliev, G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.015 · Cited by 211
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance
Fatma, H., Maurya, S., & Siddique, H. R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.008 · Cited by 185
Short-chain fatty acids activate acetyltransferase p300
Thomas, S. P., & Denu, J. M. (2021) · eLife · doi:10.7554/elife.72171 · Cited by 168
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs
Xiao, Y., Wang, J., Zhao, L., Chen, X., Zheng, G., Zhang, X., & Liao, D. (2020) · Chemical Communications · doi:10.1039/d0cc03243c · Cited by 131
Self-citation
Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications
Sher, G., Salman, N. A., Khan, A. Q., Prabhu, K. S., Raza, A., Kuliński, M., Dermime, S., Haris, M., Junejo, K., & Shahab Uddin, M. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.009 · Cited by 114
Now open: Evolving insights to the roles of lysine acetylation in chromatin organization and function
Chen, Y.-J. C., Koutelou, E., & Dent, S. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.004 · Cited by 110
Regulation of cancer stem cells in triple negative breast cancer
Fultang, N., Chakraborty, M., & Peethambaran, B. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.106 · Cited by 101
The role of altered protein acetylation in neurodegenerative disease
Kabir, F., Atkinson, R., Cook, A. L., Phipps, A. J., & King, A. E. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1025473 · Cited by 75
Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy
Cotechini, T., Atallah, A., & Grossman, A. (2021) · Cells · doi:10.3390/cells10040960 · Cited by 74
Histone deacetylase 7: a signalling hub controlling development, inflammation, metabolism and disease
Wang, Y., Abrol, R., Mak, J. Y. W., Gupta, K. D., Ramnath, D., Karunakaran, D., Fairlie, D. P., & Sweet, M. J. (2022) · FEBS Journal · doi:10.1111/febs.16437 · Cited by 67
Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer
Waddell, A. R., Mahmud, I., Ding, H., Huo, Z., & Liao, D. (2021) · Cancers · doi:10.3390/cancers13112799 · Cited by 62
Cancer stem cells: Recent insights and therapies
Zhou, H., Tan, L., Liu, B., & Guan, X. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115441 · Cited by 63
Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
Yeon, M., Kim, Y., Jung, H. S., & Jeoung, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00486 · Cited by 60
Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior
Kumar, V. E., Nambiar, R., Souza, C. D., Nguyen, A. D., CHIEN, J. R., & Lam, K. S. (2022) · Cells · doi:10.3390/cells11091403 · Cited by 61
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55
Revealing the role of miRNA-489 as a new onco-suppressor factor in different cancers based on pre-clinical and clinical evidence
Paskeh, M. D. A., Mirzaei, S., Orouei, S., Zabolian, A., Saleki, H., Azami, N., Hushmandi, K., Baradaran, B., Hashmi, M., Aref, A. R., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.09.089 · Cited by 55
Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma
Xu, Y., Liao, W., Luo, Q., Yang, D., & Pan, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.761046 · Cited by 52
Super-enhancers complexes zoom in transcription in cancer
Wang, M., Chen, Q., Wang, S., Xie, H., Liu, J., Huang, R., Xiang, Y., Jiang, Y., Tian, D., & Bian, E. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02763-5 · Cited by 51
Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer
Dai, M., Yang, B., Chen, J., Liu, F., Zhou, Y., Zhou, Y., Xu, Q., Jiang, S., Zhao, S., Li, X., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.024 · Cited by 49
H3K27ac‐activated LINC00519 promotes lung squamous cell carcinoma progression by targeting miR‐450b‐5p/miR‐515‐5p/YAP1 axis
Ye, P., Lv, X., Rusidanmu, A., Cheng, J., Xia, P., & Meng, D. (2020) · Cell Proliferation · doi:10.1111/cpr.12797 · Cited by 43
Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way
Li, W., Wu, H., Sui, S., Wang, Q., Xu, S., & Pang, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.736935 · Cited by 42
The role of protein acetylation in carcinogenesis and targeted drug discovery
Yang, J., Song, C., & Zhan, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.972312 · Cited by 42
Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets
Bacabac, M. S., & Xu, W. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10103-4 · Cited by 41
Transcriptional regulation of cancer stem cell: regulatory factors elucidation and cancer treatment strategies
Zhang, Z., & Zhang, Y. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03021-y · Cited by 39
The role of histone acetylation in transcriptional regulation and seed development
Chen, Y., Guo, P., & Dong, Z. (2023) · PLANT PHYSIOLOGY · doi:10.1093/plphys/kiad614 · Cited by 36
Acetylation in pathogenesis: Revealing emerging mechanisms and therapeutic prospects
Jiang, N., Li, W., Jiang, S., Xie, M., & Liu, R. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115519 · Cited by 38
KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote the progression of head and neck squamous cell carcinoma
Cai, H., Liang, J., Jiang, Y., Wang, Z., Li, H., Wang, W., Wang, C., & Hou, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02996-y · Cited by 35
WNT5A promotes the metastasis of esophageal squamous cell carcinoma by activating the HDAC7/SNAIL signaling pathway
Feng, Y., Ma, Z., Pan, M., Xu, L., Feng, J., Zhang, Y., Shao, C., Guo, K. X., Duan, H., Zhang, Y., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04901-x · Cited by 33
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets
Liu, S., Dai, W., Jin, B., Jiang, F., Huang, H., Hou, W., Lan, J., Jin, Y., Peng, W., & Pan, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02033-8 · Cited by 35
HDAC7 drives glioblastoma to a mesenchymal-like state via LGALS3-mediated crosstalk between cancer cells and macrophages
Zhao, S., Zhao, R., Wang, C., Ma, C., Gao, Z., Li, B., Qi, Y., Qiu, W., Pan, Z., Wang, S., et al. (2024) · Theranostics · doi:10.7150/thno.100939 · Cited by 31
Micro‐Topographies Induce Epigenetic Reprogramming and Quiescence in Human Mesenchymal Stem Cells
Vermeulen, S., Puyvelde, B. V., del Barrio, L. B., Almey, R., van der Veer, B. K., Deforce, D. L. D., Dhaenens, M., & de Boer, J. (2022) · Advanced Science · doi:10.1002/advs.202203880 · Cited by 29
Super enhancers—Functional cores under the 3D genome
Zhang, J., Yue, W., Zhou, Y., Liao, M., Chen, X., & Hua, J. (2020) · Cell Proliferation · doi:10.1111/cpr.12970 · Cited by 25
Self-citation
HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates
Mak, J. Y. W., Wu, K., Gupta, P. K., Barbero, S., McLaughlin, M. G., Lucke, A. J., Tng, J., Lim, J., Loh, Z., Sweet, M. J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01967 · Cited by 28
Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer
Cao, L., Zhao, S., Yang, Q., Shi, Z., Liu, J., Pan, T., Zhou, D., & Zhang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.614458 · Cited by 28
Targeting Histone Modifications in Bone and Lung Metastatic Cancers
Edwards, C. M., & Johnson, R. W. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00670-2 · Cited by 28
VPA improves ferroptosis in tubular epithelial cells after cisplatin-induced acute kidney injury
Li, Y., Li, K., Zhao, W., Wang, H., Xue, X., Chen, X., Li, W., Xu, P., Wang, K., Liu, P., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1147772 · Cited by 26
Self-citation
OIP5‑AS1 modulates epigenetic regulator HDAC7 to enhance non‑small cell lung cancer metastasis via miR‑140‑5p
Mei, J., Liu, G., Wang, W., Xiao, P., Yang, D., Bai, H., & Li, R. (2020) · Oncology Letters · doi:10.3892/ol.2020.11868 · Cited by 26
Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer
Xiang, X.-S., Li, P., Wang, W., & Liu, L. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188676 · Cited by 23
Histone deacetylase (HDACs) inhibitors: Clinical applications
Shanmukha, K. D., Paluvai, H., Lomada, S. K., Gokara, M., & Kalangi, S. K. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.02.011 · Cited by 26
Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro
NouriEmamzaden, F., Word, B. R., Cotton, E., Hawkins, A., Littlejohn, K., Moore, R. J., Miranda-Carboni, G., Orish, C. N., & Lyn‐Cook, B. D. (2020) · Anticancer Research · doi:10.21873/anticanres.14356 · Cited by 25
TBX2 acts as a potent transcriptional silencer of tumour suppressor genes through interaction with the CoREST complex to sustain the proliferation of breast cancers
McIntyre, A. J., Angel, C. Z., Smith, J. S., Templeman, A., Beattie, K., Beattie, S., Ormrod, A., Devlin, E., McGreevy, C., Bothwell, C., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac494 · Cited by 23
Superenhancers as master gene regulators and novel therapeutic targets in brain tumors
Zhuang, H.-H., Qu, Q., Teng, X.-Q., Dai, Y.-H., & Qu, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00934-0 · Cited by 24
A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture
Meyer, L., Jackson, H. W., Eling, N., Zhao, S., Usui, G., Dakhli, H., Schraml, P., Dettwiler, S., Elfgen, C., Varga, Z., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.019 · Cited by 25
The Multiple Faces of NANOG in Cancer: A Therapeutic Target to Chemosensitize Therapy-Resistant Cancers
Fatma, H., Siddique, H. R., & Maurya, S. K. (2021) · Epigenomics · doi:10.2217/epi-2021-0228 · Cited by 21
Super-enhancer-associated gene CAPG promotes AML progression
Ma, Q., Zhao, M., Long, B., & Li, H. (2023) · Communications Biology · doi:10.1038/s42003-023-04973-1 · Cited by 21
Super-Enhancers and Their Parts: From Prediction Efforts to Pathognomonic Status
Vasileva, A. V., Gladkova, M. G., Ashniev, G. A., Osintseva, E. D., Орлов, А. В., Kravchuk, E. V., Boldyreva, A., Burenin, A. G., Nikitin, P. I., & Orlova, N. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063103 · Cited by 24
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin
Kamran, M. Z., Bhattacharya, U., Omar, M., Marchionni, L., & Ince, T. A. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00474-2 · Cited by 20
Self-citation
Histone modification in podocyte injury of diabetic nephropathy
Wang, S., Zhang, X., Wang, Q., & Wang, R. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02247-7 · Cited by 21
Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
Sato, Y., Tomita, M., Soga, T., Ochiai, A., & Makinoshima, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.718675 · Cited by 19
Experimental Validation and Prediction of Super-Enhancers: Advances and Challenges
Kravchuk, E. V., Ashniev, G. A., Gladkova, M. G., Орлов, А. В., Vasileva, A. V., Boldyreva, A., Burenin, A. G., Skirda, A. M., Nikitin, P. I., & Orlova, N. N. (2023) · Cells · doi:10.3390/cells12081191 · Cited by 20
A Bayesian semi-parametric model for thermal proteome profiling
Fang, S., Kirk, P., Bantscheff, M., Lilley, K. S., & Crook, O. M. (2021) · Communications Biology · doi:10.1038/s42003-021-02306-8 · Cited by 18
MiR-342-3p inhibits LCSC oncogenicity and cell stemness through HDAC7/PTEN axis
Xu, C., Sun, W., Liu, J., Pu, H., & Li, Y. (2021) · Inflammation Research · doi:10.1007/s00011-021-01521-7 · Cited by 17
Epigenetic Mechanisms beyond Tumour–Stroma Crosstalk
Gagliano, T., & Brancolini, C. (2021) · Cancers · doi:10.3390/cancers13040914 · Cited by 19
Super-enhancer omics in stem cell
Ma, H., Qu, J., Pang, Z., Luo, J., Yan, M., Xu, W.-X., Zhuang, H., Liu, L., & Qu, Q. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02066-z · Cited by 23
Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative in silico study
Kashyap, K., & Kakkar, R. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1711191 · Cited by 16
HDAC7: a promising target in cancer
Liu, C., Zheng, D., Pu, X., & Li, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1327933 · Cited by 18
HDAC inhibitors as a potential therapy for chemotherapy-induced neuropathic pain
Manengu, C., Zhu, C., Zhang, G., Tian, M., Lan, X., Tao, L., Ma, L., Liu, Y., Yu, J., & Liu, N. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01488-x · Cited by 18
HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple‑negative breast cancer
Zhu, M., Liu, N., Lin, J., Wang, J., Lai, H., & Liu, Y. (2022) · Oncology Letters · doi:10.3892/ol.2022.13619 · Cited by 15
Phase separation drives tumor pathogenesis and evolution: all roads lead to Rome
Gu, X., Zhuang, A., Yu, J., Chai, P., Jia, R., & Ruan, J. (2022) · Oncogene · doi:10.1038/s41388-022-02195-z · Cited by 15
Stem Cells: Therapeutic Implications in Chemotherapy and Radiotherapy Resistance in Cancer Therapy
Patil, T. P., Rohiwal, S. S., & Pandey-Tiwari, A. (2022) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x17666221003125208 · Cited by 15
HDAC7/c-Myc signaling pathway promotes the proliferation and metastasis of choroidal melanoma cells
Zhang, Y., Ding, P., Wang, Y., Shao, C., Guo, K. X., Yang, H., Feng, Y., Ning, J., Pan, M., Wang, P., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-022-05522-0 · Cited by 14
Mechanism by which HDAC3 regulates manganese induced H3K27ac in SH-SY5Y cells and intervention by curcumin
Liu, Y., Zhao, H. Y., Yang, Y., Liu, Y., Ao, C.-Y., Zeng, J.-M., Ban, J.-Q., & Li, J. (2023) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2023.109878 · Cited by 13
Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function
Jin, Y., Qi, X., Yu, X., Cheng, X., Chen, B., Wu, M., Zhang, J., Yin, H., Lu, Y., Zhou, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.01.021 · Cited by 13
Ellagitannin Punicalagin Disrupts the Pathways Related to Bacterial Growth and Affects Multiple Pattern Recognition Receptor Signaling by Acting as a Selective Histone Deacetylase Inhibitor
Liu, F., Smith, A. D., Wang, T. T. Y., Pham, Q., Yang, H., & Li, R. W. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c08738 · Cited by 12
Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies
Rubatto, M., Borriello, S., Sciamarrelli, N., Pala, V., Tonella, L., Ribero, S., & Quaglino, P. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000926 · Cited by 13
Rational Design and Development of HDAC Inhibitors for Breast Cancer Treatment
Mody, D., Bouckaert, J. M. J., Savvides, S. N., & Gupta, V. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210917143953 · Cited by 13
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide
Bhattacharya, U., Kamran, M. Z., Manai, M., Cristofanilli, M., & Ince, T. A. (2023) · Cancers · doi:10.3390/cancers15020332 · Cited by 12
Self-citation
In Silico Identification of Promising New Pyrazole Derivative-Based Small Molecules for Modulating CRMP2, C-RAF, CYP17, VEGFR, C-KIT, and HDAC—Application towards Cancer Therapeutics
Bennani, F. E., Karrouchi, K., Doudach, L., Scrima, M., Rahman, N., Rastrelli, L., Tallei, T. E., Rudd, C. E., Faouzi, M. E. A., & Ansar, M. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44110361 · Cited by 11
The GOLM1-ACLY pathway regulates macrophage-secreted EFEMP1 via H3K27ac modifications to drive tumor progression
Zhen, L., Min, M., Mo, X., Zhao, G., Li, H., Liu, M., Wan, L., Yang, X., Huang, L., Zhang, Y., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.07.003 · Cited by 10
The epigenetic regulation of cancer cell recovery from therapy exposure and its implications as a novel therapeutic strategy for preventing disease recurrence
Appiah, C. O., Singh, M., May, L., Bakshi, I., Vaidyanathan, A., Dent, P., Ginder, G. D., Grant, S., Bear, H. D., & Landry, J. W. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.11.001 · Cited by 9
The Role of GREMLIN1, a Bone Morphogenetic Protein Antagonist, in Cancer Stem Cell Regulation
Gao, Y., De, S., & Brazil, D. P. (2025) · Cells · doi:10.3390/cells14080578 · Cited by 9
Class IIa HDACs Are Important Signal Transducers with Unclear Enzymatic Activities
Brancolini, C. (2025) · Biomolecules · doi:10.3390/biom15081061 · Cited by 8
Super-enhancer landscape rewiring in cancer: The epigenetic control at distal sites
Giorgio, E. D., Benetti, R., Kerschbamer, E., Xodo, L. E., & Brancolini, C. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.03.013 · Cited by 9
Histone Deacetylase 7 Gene Overexpression Is Associated with Poor Prognosis of Triple-Negative Breast Cancer Patients
Uzelac, B., Krivokuća, A., Šušnjar, S. V., Milovanović, Z., & Šupić, G. (2021) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2020.0138 · Cited by 8
The role and application of transcriptional repressors in cancer treatment
Park, M., Kang, K. W., & Kim, J. W. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01427-4 · Cited by 8
HDAC1-Mediated lncRNA Stimulatory Factor of Follicular Development to Inhibit the Apoptosis of Granulosa Cells and Regulate Sexual Maturity through miR-202-3p-COX1 Axis
Zhou, X., He, Y., Quan, H., Pan, X., Zhou, Y., Zhang, Z., Yuan, X., & Li, J. (2023) · Cells · doi:10.3390/cells12232734 · Cited by 7
Toxin protein LukS-PV targeting complement receptor C5aR1 inhibits cell proliferation in hepatocellular carcinoma via the HDAC7–Wnt/β-catenin axis
Shi, L., Zhang, S., Liu, G., Nie, Z., Ding, P., Chang, W., Dai, Y., & Ma, X. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108148 · Cited by 7
Scaffolding Activities of Pseudodeacetylase HDAC7
Kodikara, I. K. M., & Pflum, M. K. H. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00753 · Cited by 6
H3K27ac Is Essential for Human Naive Pluripotency Modulated by m6A‐Driven EP300 Expression
An, C., Zhong, K., Kang, X., Zhang, Y., Shang, Y., Liu, H., Ji, Y., Zeng, J., Lin, J., Jin, L. G., et al. (2025) · Advanced Science · doi:10.1002/advs.202507549 · Cited by 5
Pathogenic role of super-enhancers as potential therapeutic targets in lung cancer
Yao, Z., Song, P., & Jiao, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1383580 · Cited by 6
Acetylation and deacetylation dynamics in stress response to cancer and infections
Li, L., Zeng, Y., Cheng, G., & Yang, H. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101957 · Cited by 5
Inhibition of HDAC7 reprograms the histone H3.3 landscape to induce heterochromatin spreading and DNA replication defects in cancer cells
Hassan, O., Pizzagalli, M. D., Leary, O. P., Zepecki, J. P., Corseri, A., Wu, L. J., Sasipalli, S., Lee, D., Hayward, L., Tran, L. H., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110732 · Cited by 5
Upregulation of OATP1A2 in human oesophageal squamous cell carcinoma cells via the HDAC6-GCN5/PCAF-H3K9Ac axis
Zheng, X., Zhang, J. V., Bai, Y., Wang, J., Jiang, M., Zeng, S., & Wang, L. (2021) · Xenobiotica · doi:10.1080/00498254.2021.2001076 · Cited by 5
End binding-3 inhibitor activates regenerative program in age-related macular degeneration
Lee, Q. S., Chan, W. C., Qu, X., Sun, Y., Abdelkarim, H., Le, J., Saqib, U., Sun, M., Kruse, K. J., Banerjee, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101223 · Cited by 5
HDAC7 promotes ovarian cancer malignancy via AKT / mTOR signalling pathway
Feng, Q., Sheng, H., Liu, X., Yan, Z., Sheng, K., Li, Y., Zhang, P., & Sheng, X. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70120 · Cited by 4
Disruption of histone acetylation homeostasis reveals multilayered chromatin regulation for transcriptional resiliency
Venu, V., Small, E. M., Roth, C., Adikari, S., Vlot, A. H. C., Sullivan, K. A., Abeyratne, C. R., Jacobson, D., Starkenburg, S. R., Sanbonmatsu, K. Y., et al. (2025) · Epigenetics & Chromatin · doi:10.1186/s13072-025-00631-4 · Cited by 6
Alterations of histone modifications in cancer
Saber-Ayad, M. M., Ramadan, W. S. H., & El‐Awady, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18661-5.00018-x · Cited by 5
A Regulative Epigenetic Circuit Supervised by HDAC7 Represses IGFBP6 and IGFBP7 Expression to Sustain Mammary Stemness
Giorgio, E. D., Cutano, V., Minisini, M., Tolotto, V., Dalla, E., & Brancolini, C. (2021) · Epigenomics · doi:10.2217/epi-2020-0347 · Cited by 4
HDAC7 influences ER-⍺ transcription via NCoR-HDAC3 dissociation
Kodikara, I. K. M., Nwanelo, V. O., Belanger, A. K., & Pflum, M. K. H. (2025) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2025.141083 · Cited by 3
Epigenetics in precision medicine of breast cancer
Natesh, J., Penta, D., & Meeran, S. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823008-4.00004-4 · Cited by 3
Tweety homolog 3 promotes colorectal cancer progression through mutual regulation of histone deacetylase 7
Lu, P., Deng, S., Liu, J., Xiao, Q., Zhou, Z., Li, S., Xin, J., Shu, G., Yi, B., & Yin, G. (2024) · MedComm · doi:10.1002/mco2.576 · Cited by 3
Anti-cancer Mechanisms and Applications of Cinnamon Extract: A Comprehensive Review
Chen, X., Cai, Y., & Xie, Z. (2025) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-025-4136-y · Cited by 2
Self-citation
HDAC inhibition in cancer
Rathinavelu, A., & Natarajan, U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823931-5.00017-7 · Cited by 2
Novel histone acetylation-related lncRNA signature for predicting prognosis and tumor microenvironment in esophageal carcinoma
Han, B., Ma, Y., Yang, P., Zhao, F., Zhu, H., Li, S., Yu, R., & Bao, S. (2024) · Aging · doi:10.18632/aging.205636 · Cited by 2
Defining the heterogeneous molecular landscape of lung cancer cell responses to epigenetic inhibition
Lin, C., Sniezek, C. M., McGann, C. D., Karki, R., Giglio, R. M., Garcia, B. A., McFaline‐Figueroa, J. L., & Schweppe, D. K. (2026) · Communications Biology · doi:10.1038/s42003-025-09455-0 · Cited by 2
Immunohistochemical Evaluation of p300, H2AacK5 and H3AcK27 in Odontogenic Cysts and Tumors
Carvalho, L. D. J., Guimarães, D. M., Souza, A. T. P., Balbinot, K. M., Kataoka, M. S. D. S., Júnior, S. D. M. A., Nunes, F. D., da Silva, M. J. C. N., & Pinheiro, J. D. J. V. (2024) · Oral Diseases · doi:10.1111/odi.15164 · Cited by 1
Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7 ‐mutated colorectal cancer
Tolotto, V., Gualandi, N., Cortolezzis, Y., Picco, R., Colitti, M., D’Este, F., Gani, M., Hancock, W. W., Terrosu, G., Degrassi, C., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70152 · Cited by 2

Authors: Caslini, C., Hong, S., Ban, Y. J., Chen, X. S., & Ince, T. A.
Affiliations: University of Miami (US)
Corresponding author: Caslini, Corrado
Ince, Tan A.
ORCID: Caslini, Corrado
Hong, Sunhwa
Ban, Yuguang J.
Ince, Tan A.
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2019-08-02
Volume: 38
Issue: 39
Pages: 6599-6614
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/s41388-019-0897-0
OpenAlex: W2966048051
Cited by: 121
References: 45
Citations by year: 2026: 9 · 2025: 17 · 2024: 19 · 2023: 25 · 2022: 18 · 2021: 21 · 2020: 11
FWCI: 4.22
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Oncogene (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: Breast Cancer Research Foundation
Florida Breast Cancer Foundation
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords: HDAC7, HDAC1, HDAC3, histone deacetylase, super-enhancers, breast cancer stem cells, transcriptional regulation, chromatin regulation, transcription start sites, histone deacetylase inhibitors, breast cancer
MeSH terms: Histone Deacetylase 3, Acetylation, Benzamides, Breast Neoplasms, Enhancer Elements, Genetic, Female, Histone Deacetylases, Histones, Humans, Lysine, Pyridines, Transcription Factors, Transcription, Genetic, Neoplastic Stem Cells, Down-Regulation, Gene Knockdown Techniques, Histone Deacetylase 1, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks